Loading
A phase 2 trial of Temozolomide, Silevertinib in brain and spinal cord tumours, run by Black Diamond Therapeutics, Inc., now recruiting.
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII is a phase 2 interventional study registered as NCT07326566 by Black Diamond Therapeutics, Inc., with 162 participants planned, started 2026-05-05 and due to reach its primary completion in 2028-11. Interventions recorded: silevertinib in combination with temozolomide, temozolomide (TMZ). Conditions listed: Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Silevertinib, Black Diamond Therapeutics.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy.
Shares Brain and spinal cord tumours (all types), Temozolomide, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/